We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Streamlined Assay Improves Prenatal Detection of Alpha-Thalassemia

By LabMedica International staff writers
Posted on 09 Jun 2020
Alpha-Thalassemia is a group of recessively inherited hemoglobin (Hb) disorders that result from decreased or absent synthesis of α-globin chains, affecting up to 5% of the world's population, mainly prevalent in the Mediterranean coastal countries, Southeast Asia, some African countries, and southern China.

Thalassemia is a group of inherited blood disorders that reduces the ability of blood to circulate oxygen throughout the body. More...
The severity can vary from benign to life threatening; therefore, it is important to identify infants as early as possible who may develop thalassemia-associated symptoms, as well as parents who are carriers. This requires the availability of practical and precise molecular diagnostic tools.

Scientists at the Southern Medical University (Guangzhou, China) developed a rapid, accurate novel assay for non-deletional alpha-thalassemia genotyping based on one-step nested asymmetric polymerase chain reaction (PCR) melting curve analysis, which may enhance prenatal diagnosis, newborn screening, and large-scale population screening. To assess the assay for mass screening, 1,250 blood samples referred to their laboratory for the molecular diagnosis of α-thalassemia were randomly selected. The genomic DNA (gDNA) samples were extracted from peripheral blood lymphocytes using TIANamp Blood DNA Kit (TianGen Biotech Co, Ltd, Beijing, China). The assay was a one-step closed-tube genotyping method that involved nested asymmetric PCR and melting curve analysis running on a Bio-Rad CFX96 Real-Time PCR Platform (Bio-Rad, Hercules, CA, USA).

The investigators tested the ability of the new assay to detect five non-deletional alpha-thalassemia mutations. All five mutations were accurately identified with a concordance rate of 100% in a blind analysis of 255 samples with known genotypes, as determined by other analytic methods including gap-PCR, PCR-reverse dot blot (RDB), or Sanger sequencing. The investigators also tested the capability of the new assay to screen large populations. After testing 1,250 blood samples, the assay showed 100% sensitivity and specificity for all of the targeted mutations. The overall analysis time with the new assay was just under 2.5 hours. This is considerably faster than other molecular genetic testing methods, such as Sanger sequencing, which require 380 minutes, or RDB, which takes 300 minutes.

Wanjun Zhou, PhD, a medical geneticist and senior author of the study, said, “These other methods are unsuitable for use in large-scale screening programs because they have limitations such as cumbersome operation, low throughput, subjective interpretation, and possible laboratory contamination caused by post-PCR open-tube operation. Our results prove that this new assay is accurate, reliable, simple, and rapid and can meet the requirements for clinical diagnosis and mass screening of non-deletional alpha-thalassemia”.

The authors concluded that an assay of nested asymmetric PCR melting analysis for rapid and accurate genotyping of non-deletional α-thalassemia has been established, including the mutations of WS (HBA2: c.369C>G), QS (HBA2: c.377T>C), CS (HBA2: c.427T>C), CD30 (HBA2: c.91_93delGAG), and CD31 (HBA2: c. 95G>A). Moreover, the strategy of this study can effectively overcome the bottleneck of high homology and GC-rich secondary structure. The study was published on May 29, 2020 in The Journal of Molecular Diagnostics.

Related Links:
Southern Medical University
TianGen Biotech Co



New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
PSA Assay
CanAg PSA EIA
New
Integrated Biochemical & Immunological System
Biolumi CX8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.